Your SlideShare is downloading. ×
Surgical management of mammary tumour in canines
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Surgical management of mammary tumour in canines

558
views

Published on

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
558
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
18
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. “ SURGICAL MANAGEMENT OF MAMMARY TUMOUR IN CANINE” Presented By – Dr. Manzoor Ahmad bhat m. v. sc. Scholar Department of Veterinary Surgery and Radiology
  • 2. MAMMARY TUMOUR (MT)
    • Neoplasia which involve mammary gland
    • Most common in bitches, rare in male(1%)
    • MT consist of 50% of all tumours in bitch
    • Malignant or benign
    • 30% to 50% are malignant
    • malignant tumours spread through lymphatics and blood vessels primarily to regional lymph nodes and lungs
    • Other metastatic sites include adrenal glands, kidneys, heart and bones
    20/11/2010
  • 3. PATHOLOGICAL ASPECT
    • Benign tumours are usually fibroadenoma, adenomas or mesenchymal tumours
    • Most malignant tumours are carcinomas and these tend to spread after surgery
    20/11/2010
  • 4. ETIOLOGY
    • Unknown
    • Hormone dependent
    • Estrogen and progesterone seems to have a role
    • Estrogen and progesterone receptors are found in 50% malignant and 70% of benign canine MTs
    20/11/2010
  • 5. OHE AND MAMMARY TUMOUR
    • MT are prevented if OHE is done before 1 year of age
    • Risk of developing MT is only 0.05% in bitches spayed before 1 st estrous
    • Risk increases to 8% and 26% after 1st and 2 nd estrous respectively
    • No effect of OHE on MT after 2.5years
    20/11/2010
  • 6. CASE HISTORY
        • Case no.
        • Date: 7/10/10
        • Spp: canine
        • Breed: labrador
        • Age: 10 years
        • Sex: Female
        • Colour: fawn
        • Weight: 27 kg
    20/11/2010
  • 7. HISTORY
    • Hard lump present on abdomen for last 2 months
    • Fast growing
    • Non pregnant and non lactating for last 2 years
    • Engorgement of teats before 6 month
    20/11/2010
  • 8. PHYSICAL FINDINGS
    • Tumour like growth of about 12cm diameter involving 2 nd right teat
    • Ulcerated growth was firm but easily movable below the skin
    • All physiological parameters were found to be normal
    • Right axillary lymph nodes were palpable (slight swollen)
    20/11/2010
  • 9. DIAGNOSIS 20/11/2010
    • Based on history and visual observation
    Mammary Tumour
  • 10. TREATMENT
    • Medicinal management
    • Antiestrogens (tamoxifen @0.4 to 0.8mg/kg/d PO), antiprogestins or antiprolactins are advocated by some.
    • Chemotherapy but no particular protocol. Adriamycin and cyclophosphamide combinations are used
    • Radiation therapy
    • Immunotherapy
    • Surgical excision is the treatment of choice
    • So it was adopted with out any delay
    20/11/2010
  • 11. PREOPERATIVE MANAGEMENT
    • 0.5mg/kg of Pheneramine maleate was given i/m
    • 1ml of dexamethasone s/c
    • Carbazochrome salicylate 1ml i/m
    20/11/2010
  • 12. PRE ANESTHETICS
    • Triflupromazine HCL @ 1mg/kg body weight i/v
    • Atropine sulphate @0.04mg/kg body weight s/c
    20/11/2010
  • 13. PREPARATION OF SURGICAL SITE
    • Savlon was applied on the intended area and shaving was done liberally to prepare the site
    20/11/2010
  • 14. ANESTHESIA
    • Thiopentone Na @ 20mg/kg body weight i/v
    • 5% solution was prepared and 1/3 rd was sufficient for induction
    • 2/3 rd was used for maintenance
    • Total dose of 300mg was sufficient for the whole surgical procedure to complete successfully
    20/11/2010
  • 15. SURGICAL PROCEDURE 20/11/2010
  • 16. POST-OPERATIVE THERAPY
    • Antibiotics – ceftriaxone 500 mg i/m for 5 days
    • NSAID- meloxicam @ 0.5 mg/kg for 5 days
    • Antihistaminic- pheneramine maleate
    • @ 0.5mg/kg for 4 more days
    • RL 200ml i/v for 2days
    • Daily dressing of surgical wound for 5 days.
    20/11/2010
  • 17. 20/11/2010

×